SEC Form 4 · accession 0001140361-18-032716
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
V Bryan Lawlis
Director
Period of report
Jul 13, 2018
Accepted (ET)
Jul 17, 2018 · 4:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636282
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F1 | $8.78 | Jul 13, 2018 | A | 36,800 | A | — | Jul 12, 2028 | Common Stock | 36,800 | 36,800 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable in 36 equal monthly installments beginning on August 13, 2018, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.